Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance

Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance

H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8%1 and core operating income of €845m, growing by 28.8% as reported, with a core operating margin…

Ipsen has 'firepower' for more deals with €2B war chest

Ipsen has its eyes trained on more M&A — and has €2 billion worth of “firepower” to do it, based on its cash position at the end of June, CFO Aymeric Le Chatelier said. “If we ...

SES Reports H1 2026 Results & Reiterates Full-Year Outlook

LUXEMBOURG--(BUSINESS WIRE)--SES S.A. announces financial results for the three and six months ended June 30, 2026. H1 2026 Performance (€ million) H1 2026 as reported (1) H1 2025 as reported (1) ∆ At constant FX (2) H1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.17 1.08   1.08   Revenue 1,602 978 +72.4% 1,799 -5.0% Adjusted EBITDA (4) 725 521 +47.0% 824 -6.2% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17…